REGN Regeneron Pharmaceuticals, Inc.

Regeneron’s Rare Disease Drug Shows Zero New Abnormal Bone Growth In Extended Trial – REGN Stock Heads For Best Day In Over A Month $REGN $XBI https://stocktwits.com/news/equity/markets/regeneron-rare-disease-drug-shows-zero-new-abnormal-bone-growth-in-extended-trial/cZxIKyORB8j

$REGN $SNY — Confirmed $8B immunology expansion: Regeneron Pharmaceuticals and Sanofi expanded their long-running immunology partnership to cover four next-generation long-acting antibodies. Sanofi will pay Regeneron $1B upfront, with REGN eligible for up to another $7B in milestones. Future development/commercialization costs and profits will be shared 50/50. Sanofi One program, REGN20423, is already in Phase 1 for atopic dermatitis, with three additional antibodies expected to enter clinical trials in 2027. Importantly, the existing economics around blockbuster Dupixent remain unchanged. This is a substantial validation of Regeneron's next-generation immunology pipeline, not merely an early-stage research collaboration.

$REGN For long term plays from Monday (still woking on deciding the holding period), #REGN has good potential $MU $CIEN

$REGN (Regeneron) renews its partnership with Sanofi, which will pay $1.X billion upfront plus up to $7.X billion in milestones to develop next-generation antibodies as a successor to Dupixent, whose patent expires in 2031, led by REGN20423 in Phase 1 for atopic dermatitis.

Thursday’s biggest analyst calls: UBS upgrades Regeneron to buy from neutral StoneX initiates ON Semiconductor as buy Barclays upgrades Crocs to overweight from equal weight StoneX downgrades Spotify to hold from buy Deutsche Bank upgrades Walmart to buy from hold $REGN $ON $CROX $SPOT $WMT

$REGN must have paid huge price for not letting it fall, amazing, better close above or else this will just get roll over for tomorrow

$REGN presented fresh ESMO 2026 data, highlighting late-stage Libtayo survival in high-risk CSCC and new Factor XI thrombosis studies.

$REGN $SNY Sanofi is paying Regeneron 1 billion upfront for four long-acting antibodies meant to carry the franchise past Dupixent's patent cliff. The structure goes up to 8 billion total: 1 billion now, another 7 billion in milestones. The catch is timing. The lead asset (REGN20423, an IL-13 antibody for eczema) is still in Phase 1, and the other three don't reach the clinic until 2027. One level down, this is Sanofi buying the Dupixent sequel before it needs one. Dupixent protection starts lapsing in the early 2030s, so the 1 billion is a franchise-continuity premium on mostly preclinical assets. Costs and profits split 50/50, Regeneron runs R&D, Sanofi runs global sales. The deal also settles the 2024 lawsuit between the two. New Sanofi CEO Belen Garijo closed it in her first five months; her predecessor tried and failed to expand the alliance (per Barclays via Reuters).

Regeneron, Sanofi Expand Immunology Alliance With $1B Upfront Payment: Here Are The Key Highlights $REGN $SNY https://stocktwits.com/news/equity/markets/regeneron-sanofi-expand-immunology-alliance-with-1-b-upfront-payment-here-are-the-key-highlights/cZD0cNjRBiZ

$REGN UBS moved to Buy from Neutral and took its target from 660 to 978, up 48%, centered on Dupixent's longer-term growth. Stock was around 797 Friday, consensus target is 845. Q3 lands Oct 30. Last print was Q2: revenue 4.29B, up 16.7%, EPS 14.29 against 10.16 expected.

🟢 $REGN 840C Oct 23 💰 $237,200 premium 💵 $5.93/contract 📊 1218.8x Vol/OI 📍 Spot $795 💰 Large premium | 🔥 1218.8x Vol/OI | 🚨 Repeat sweep 🌊 Dark Flow | Options Flow